BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer. - Wikidata - wikimedia - TriplyDB

BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer.

BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer.

http://www.wikidata.org/entity/Q37242277

about

Molecular Assays in Cytopathology for Thyroid Cancer Progress in molecular-based management of differentiated thyroid cancer Prognostic value of the BRAF V600E mutation in papillary thyroid carcinoma Diagnostic and prognostic TERT promoter mutations in thyroid fine-needle aspiration biopsy.BRAF V600E mutation in prognostication of papillary thyroid cancer (PTC) recurrence A meta-analysis of prognostic roles of molecular markers in papillary thyroid carcinoma Prognostic utility of BRAF mutation in papillary thyroid cancer.Molecular diagnostics of fine needle aspiration for the presurgical screening of thyroid nodules.The prognostic implication and potential role of BRAF mutation in the decision to perform elective neck dissection for thyroid cancer S100-A10, thioredoxin, and S100-A6 as biomarkers of papillary thyroid carcinoma with lymph node metastasis identified by MALDI imaging.Molecular approaches to thyroid cancer diagnosis.Cytomorphological and molecular genetic findings in pediatric thyroid fine-needle aspiration.Molecular pathogenesis and mechanisms of thyroid cancer Associations of the BRAF(V600E) mutation with sonographic features and clinicopathologic characteristics in a large population with conventional papillary thyroid carcinoma.BRAF mutation correlates with recurrent papillary thyroid carcinoma in Chinese patients A prospective study evaluating the accuracy of using combined clinical factors and candidate diagnostic markers to refine the accuracy of thyroid fine needle aspiration biopsy Association between BRAF V600E mutation and recurrence of papillary thyroid cancer.Identification of Intermediate- to High-Risk Papillary Thyroid Carcinoma Patients Who May Be Safely Managed without the Performance of Delayed Stimulated Thyroglobulin Measurements following Total Thyroidectomy and Radioactive Iodine Therapy Relevance of BRAF(V600E) mutation testing versus RAS point mutations and RET/PTC rearrangements evaluation in the diagnosis of thyroid cancer Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples BRAFV600E mutation in papillary thyroid microcarcinoma: a meta-analysis The utility of BRAF testing in the management of papillary thyroid cancer.The Risk of Relapse in Papillary Thyroid Cancer (PTC) in the Context of BRAFV600E Mutation Status and Other Prognostic Factors.Employing genetic markers to improve diagnosis of thyroid tumor fine needle biopsy.Late intervention with anti-BRAF(V600E) therapy induces tumor regression in an orthotopic mouse model of human anaplastic thyroid cancer.Three-gene molecular diagnostic model for thyroid cancer.RAS Mutations in AUS/FLUS Cytology: Does it Have an Additional Role in BRAFV600E Mutation-Negative Nodules?The Clinicopathological Features of BRAF Mutated Papillary Thyroid Cancers in Chinese Patients RET/PTC Translocations and Clinico-Pathological Features in Human Papillary Thyroid Carcinoma.Suspicious ultrasound characteristics predict BRAF V600E-positive papillary thyroid carcinoma.Differential Clinicopathological Risk and Prognosis of Major Papillary Thyroid Cancer Variants.BRAF V600E mutation and its association with clinicopathological features of papillary thyroid cancer: a meta-analysis Detection of Circulating BRAF(V600E) in Patients with Papillary Thyroid Carcinoma Clinical significance of preoperative detection of serum p53 antibodies and BRAF(V600E) mutation in patients with papillary thyroid carcinoma.Association between single-nucleotide polymorphisms of BRAF and papillary thyroid carcinoma in a Chinese population Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model.Association of BRAF V600E Mutation and MicroRNA Expression with Central Lymph Node Metastases in Papillary Thyroid Cancer: A Prospective Study from Four Endocrine Surgery Centers Is BRAF mutation associated with lymph node metastasis in patients with papillary thyroid cancer?Molecular targeting of papillary thyroid carcinoma with fluorescently labeled ratiometric activatable cell penetrating peptides in a transgenic murine model Impact of lymph node metastases identified on central neck dissection (CND) on the recurrence of papillary thyroid cancer: potential role of BRAFV600E mutation in defining CND.

P2860

Q26823658-61FB9F9F-16DF-4953-B7F5-25C1326E74C5 Q26999887-4763B134-5D36-4B8E-9592-F70CA920337B Q27852780-B9DA2BF4-3730-4DEA-A1E9-58C9E6B2ADAC Q27853057-24CB12EE-8224-453E-AEE2-62A938AE714E Q28075975-1CC1CB76-F51A-4855-BA0C-5A6E88AEED18 Q33656624-3F12E009-6A21-43C4-9CA3-E1DA84B53A14 Q33771120-D97460D3-FC50-4653-B694-82BECCA0D6E8 Q33782114-3670B62C-4EFA-4A20-8A47-EDAD258000B0 Q33973118-B80D5E98-0DCC-4FC9-ACB0-2674D4B93A1E Q34027466-05BAAD96-779A-4469-A40A-D1508289156E Q34160828-9C04B8B4-A3C6-4460-84BC-472DAC095B0C Q34273287-A1C73C28-7FC5-4E21-8CD4-3684BC744897 Q34329018-DD392962-477D-498A-8CD8-D76F19695A76 Q34388349-373882B5-5C29-4CB4-BC56-9E8E3488257E Q34637861-4C920872-71E6-45F0-877D-615F8B4C039E Q34644257-2664ED5A-F9C8-421C-A6EB-924455643CA0 Q34716574-9178A4F7-9AF5-423E-A7C2-FB7FACC50735 Q35012911-9FF1128F-8B61-4001-BAB5-1217BB872D99 Q35064835-4BDB1DB7-8877-489C-AC3E-0E9FE9A95B15 Q35497850-A721950F-749A-4286-B16F-FB7F1EE3523A Q35543644-B71CC997-4D1B-40E5-8A6B-3704A7347284 Q35583821-0645B33B-BE0F-41FC-AE5C-90422FD9F2A0 Q35692478-CBC61B62-C690-48A8-8897-10298BF3455F Q35731026-9827387A-C0BC-4E66-8899-3976A89C82C9 Q35744562-3AC662A0-720F-4ED2-BB74-5E895644F523 Q35778564-15C060B4-8025-45BE-AE84-26D817ED9426 Q35858147-F7BA642F-803A-434A-951E-3B0F30910497 Q35932262-8EB9C235-10DD-4904-9D24-D83476077CB9 Q35971877-DE97A028-0D7E-4589-994D-16A178CAB5C6 Q35979731-A52366A3-2D96-4F68-B65C-0812DD0AC894 Q36431628-E2909CD4-DE8B-4F1C-A64C-1B806728207F Q36442403-989AE997-BA29-4F05-85D0-2E0B762E3A50 Q36468764-16ECF170-7B69-4E7A-9196-65EF983A9459 Q36493086-7ED01944-FCD0-4CC7-B722-EC84221BC621 Q36515437-ACFF8F5D-6DC4-4295-A24C-4AB5C4CDEDCB Q36618887-39F53239-12E0-49AC-B10C-46318396466E Q36786213-0931C19B-7A86-4AAB-8532-A1C912ABE82A Q37023848-C39AD73E-5BB5-478C-9F83-9219DB4EF50B Q37179943-8C76005B-7B2F-4E46-979F-9AF96B39A2C5 Q37188539-05538127-2CB0-422A-8C06-2AF3239476ED

P2860

BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer.

http://www.wikidata.org/entity/Q37242277

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 04 May 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

BRAF mutation testing of thyro ...... n in papillary thyroid cancer.

@en

BRAF mutation testing of thyro ...... n in papillary thyroid cancer.

@nl

type

label

BRAF mutation testing of thyro ...... n in papillary thyroid cancer.

@en

BRAF mutation testing of thyro ...... n in papillary thyroid cancer.

@nl

prefLabel

BRAF mutation testing of thyro ...... n in papillary thyroid cancer.

@en

BRAF mutation testing of thyro ...... n in papillary thyroid cancer.

@nl

P1433

Q37242277-3074199F-6215-4D72-B8AE-76EAC49DCEE8

P1476

Q37242277-F9BF697F-DD70-41D7-B5E8-02A251EF1B7D

P2093

Q37242277-08D566F7-9D69-4ED7-9AFE-B6230405C7E5

Q37242277-1BC7DE2E-A755-4B29-8E30-443E7CDF6C7C

Q37242277-3C0400DF-25C9-4F5B-90DE-66BD30FE3095

Q37242277-49B7641A-4B5C-4F11-85D4-9EC434BC3BAE

Q37242277-5496C055-BBE7-4B39-B268-80031F2F1EA0

Q37242277-7E778379-7C84-4466-8D51-B86C5BEF956C

Q37242277-87BCADCD-7F00-4722-8696-655DFD4FA21B

Q37242277-8D17C979-193B-420F-960D-EE11EDEC4A06

Q37242277-A026573A-8767-4D50-936A-26D48E83F80B

Q37242277-CFD15F2F-3047-4986-BF38-E7CFE50DE215

P2860

Q37242277-0FA27E6A-EA92-41BB-9093-BEFF65A2F01F

Q37242277-1381BEE9-4616-4361-B50F-FC9654B873DF

Q37242277-166B7AD9-3993-47C8-9549-69B4C2B19911

Q37242277-26DB9712-FCAB-4416-B84C-918CBC09A0DA

Q37242277-32D366AB-6667-4A16-86CB-E97025E9833A

Q37242277-3B987367-B18D-4D7E-A4E2-2229AC4A1395

Q37242277-3FA301A7-8EA7-44C7-B771-621E7DB65B8D

Q37242277-437A36F3-00B7-4C6F-99C5-152D16F99EFE

Q37242277-5D80BE6C-CE4A-410C-BA45-4E3062A9656A

Q37242277-639760DC-CF79-4F8E-B167-24C57CB23641

P304

Q37242277-3EBC8B98-D70B-4D1C-A185-EF05C49FD7BE

P31

Q37242277-2EC33759-A0A2-4ADF-839E-EA54F0498B0C

P356

Q37242277-FDA360D4-8ED4-49BF-8FFC-E23BCFFE570F

P407

Q37242277-1D014A03-6666-48AB-B040-46023BED2742

P433

Q37242277-CA36F3DF-73DF-4D6D-9B02-69A3AB605E0B

P478

Q37242277-1272472B-5A87-430F-BA8F-9E76344FC108

P577

Q37242277-FB7CAEA7-464E-4577-AB77-97022E8FF297

P5875

Q37242277-DEB670C9-B2B1-4FC0-AC81-712CE034662B

P698

Q37242277-DE7BF7E6-C3C0-4099-BBFD-F88C910E176F

P921

Q37242277-0DABAED3-1497-4A7D-9D54-11E8760094B9

P932

Q37242277-BA20BDE7-0454-4983-992B-BC4A2B52FD6D

P356

JCO.2008.20.1426

P1433

Journal of Clinical Oncology

P1476

BRAF mutation testing of thyro ...... n in papillary thyroid cancer.

@en

P2093

Alan Dackiw

http://www.w3.org/2001/XMLSchema#string

Anthony Tufaro

http://www.w3.org/2001/XMLSchema#string

Douglas Clark

http://www.w3.org/2001/XMLSchema#string

Haixia Guan

http://www.w3.org/2001/XMLSchema#string

Kathryn A Carson

http://www.w3.org/2001/XMLSchema#string

Martha Zeiger

http://www.w3.org/2001/XMLSchema#string

Matthew Kim

http://www.w3.org/2001/XMLSchema#string

Meiju Ji

http://www.w3.org/2001/XMLSchema#string

Mingzhao Xing

http://www.w3.org/2001/XMLSchema#string

Paul Ladenson

http://www.w3.org/2001/XMLSchema#string

P2860

The heterogeneous distribution of BRAF mutation supports the independent clonal origin of distinct tumor foci in multifocal papillary thyroid carcinoma.

A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 [see commetns]

BRAF(V600E) mutation and the biology of papillary thyroid cancer.

Prognostic factors in well-differentiated thyroid cancer.

BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer.

Most multifocal papillary thyroid carcinomas acquire genetic and morphotype diversity through subclonal evolution following the intra-glandular spread of the initial neoplastic clone.

Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989.

Clinical review 170: A systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer.

Increased incidence of thyroid carcinoma in france: a true epidemic or thyroid nodule management effects? Report from the French Thyroid Cancer Committee.

Total thyroidectomy for differentiated thyroid cancer.

P304

2977-2982

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2008.20.1426

http://www.w3.org/2001/XMLSchema#string

P407

P433

18

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P577

2009-05-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24401003

http://www.w3.org/2001/XMLSchema#string

P698

19414674

http://www.w3.org/2001/XMLSchema#string

P921

P932

2702231

http://www.w3.org/2001/XMLSchema#string